Mr. Isa Odidi reports

INTELLIPHARMACEUTICS INTERNATIONAL INC. RECEIVES CONDITIONAL APPROVAL TO LIST ON THE TSX VENTURE EXCHANGE

IntelliPharmaCeutics International Inc. has applied and received conditional approval to list the company's common shares for trading on the TSX Venture Exchange as a Tier 2 life science issuer. Final approval of the listing on the TSX-V is subject to the company satisfying certain conditions required by the TSX-V. The company's management team is working diligently to satisfy such listing conditions. Subject to the receipt of TSX-V's final approval of listing, the company expects a seamless transition from trading on the Toronto Stock Exchange to the TSX-V. Upon listing on the TSX-V, the company expects its shares to continue to trade under the symbol IPCI. The shares will also continue to be listed on the OTCQB Marketplace in the United States under the symbol IPCIF. The company will provide further updates relating to the listing on the TSX-V and voluntarily delisting from the TSX by way of press release.

About IntelliPharmaCeutics International Inc.

IntelliPharmaCeutics International is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. The company's patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to a wide range of existing and new pharmaceuticals.

IntelliPharmaCeutics has developed several drug delivery systems based on this technology platform, with a pipeline of products (some of which have received FDA (Food and Drug Administration) approval) in various stages of development. The company has ANDA and NDA 505(b)(2) drug product candidates in its development pipeline. These include the company's abuse-deterrent oxycodone hydrochloride extended-release formulation (Oxycodone ER) based on its proprietary nPODDDS; novel Point Of Divergence Drug Delivery System (for which an NDA has been filed with the FDA), and Regabatin; XR (pregabalin extended-release capsules).

We seek Safe Harbor.